AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01276756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks
Study NCT01276756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin (> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
Study NCT01276756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
Study NCT01992627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HILTERAPIA HIRO 3.0
Description: High-intensity laser therapy (HILT), which involves higher-intensity laser radiation and which causes minor and slow light absorption by chromophores. This absorption is obtained not with concentrated light but with diffuse light in all directions (the scattering phenomenon), increasing the mitochondrial oxidative reaction and adenosine triphosphate, RNA, or DNA production (photochemistry effects) and resulting in the phenomenon of tissue stimulation called photobiology.
Study NCT04291287 — intervention group
Intervention type: DRUG
Intervention: Antithrombotic Agent
Description: Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include:~* Clopidogrel (Plavix®)~* Prasugrel (Efient®)~* Ticagrelor (Brilique®)~DOACs therapy include:~* Apixaban (Eliquis®)~* Dabigatran (Pradaxa®)~* Edoxaban (Lixiana®)~* Rivaroxaban (Xarelto®).~Oral anticoagulant therapy (OAT) include:~* Warfarin (Counmadin®)~* Acenocumarol (Sintrom®)
Study NCT01045811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing training
Description: Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
Study NCT01045811 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management
Description: Cognitive reconstructive strategies for stress management
Study NCT04544241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Survivorship Leadership Training for Clergy Wives and Widows
Description: We will meet with Clergy Wives and Widows monthly for 2-3 hours over 10 months. These sessions will be delivered using innovative online format through Zoom over the ten months. During each meeting session, experienced community and academic leaders will present their expertise with relationship to cancer survivorship and caregiving. These individuals will have extensive experience in the particular area they are presenting in. In addition, allotted time will be given for discussion and group activities that can be performed virtually. To receive credit for completion of the training program, each participant must complete the training and deliver a group workshop. All clergy wives and widows will complete a demographic questionnaire, in addition to pre- and post- intervention questionnaires
Study NCT04653181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Iron-arm treated with Ferric carboxymaltose, non-iron arm without
Study NCT00314340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity
Description: The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
Study NCT05515159 — intervention group
Intervention type: OTHER
Intervention: electroconvulsive therapy
Description: electrical stimulation of the brain while the patient is under anesthesia.
Study NCT00709280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7% Hypertonic Saline (HS)
Description: Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
Study NCT00314340 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity
Description: The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
Study NCT00709280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Isotonic Saline (IS)
Description: Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
Study NCT00314340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ER Morphine
Study NCT00314340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocodone plus acetaminophen
Study NCT00314340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00607620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Training in brief interventions for alcohol use disorders, with a focus on motivational interviewing
Study NCT04066114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lulizumab pegol
Description: 25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)
Study NCT04066114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: antithymocyte globulin (rabbit)
Description: Study participants are administered four doses of rabbit anti-thymocyte globulin, total dose 6 mg/kg given in divided doses on the day of transplantation and days 1-3.
Study NCT04066114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2
Study NCT01182012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Depending on the results of cardiovascular risk factor indexes, the treatment (including drugs, if needed) may be modified or adjusted. A nurse visit will be programmed to explain the lifestyle behaviour the patient should have.
Study NCT04070001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 Mg Ibuprofen
Description: 1-dose 400-mg ibuprofen 1-hour before elastomeric separator placement
Study NCT04070001 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser application
Description: A single irradiation of laser after elastomeric separator placement
Study NCT04070001 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: Placebo lactose tablets 1-hour before elastomeric separator placement
Study NCT03353714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal block
Description: Pudendal block with normal saline (for control group) and bupivacaine (for intervention group)
Study NCT03353714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pudendal block
Description: Pudendal block with normal saline (for control group) and bupivacaine (for intervention group)
Study NCT00997373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks
Study NCT01501539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Hydrocolloid Dressing
Description: Treatment placed over insertion site.
Study NCT01501539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silver Hydrocolloid Dressing
Description: Place dressing against skin under gastrostomy tube
Study NCT05067608 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control arm receiving normal (never before frozen) platelets as per current clinical practice
Description: Liquid platelets arm (control) and may receive multiple platelet transfusions per thrombocytopenic cycle.
Study NCT05067608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment arm receiving cryopreserved platelets
Description: Cryopreserved platelets arm (treatment) and may receive multiple platelet transfusions per thrombocytopenic cycle.
Study NCT00758901 — intervention group
Intervention type: DEVICE
Intervention: Knee Replacement (with ROCC Knee prosthesis)
Description: Knee Replacement (with ROCC Knee prosthesis)
Study NCT04066114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: 8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)
Study NCT04066114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Beginning on Day 3 post transplantation, taken orally: 60 mg daily~* Days 4 through 10: 30 mg daily~* Days 11 through 17: 20 mg daily~* Days 18 through 24: 10 mg daily~* After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol
Study NCT04066114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.
Study NCT04066114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belatacept
Description: 5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)
Study NCT04066114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: mycophenolate mofetil is started no later than one day after transplant at 1000mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do no tolerate everolimus can stay on or switch back to mycophenolate mofetil 1000 mg twice daily and remain in trial.
Study NCT04066114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolic acid
Description: mycophenolic acid is started no later than one day after transplant at 720mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do not tolerate everolimus can stay on or switch back to 720 mg twice daily of mycophenolic acid and remain in trial.
Study NCT00728819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered PICC
Description: Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
Study NCT00728819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-tapered PICC
Description: Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
Study NCT00765336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline extended release
Description: 1 mg/kg extended release minocycline HCL, once daily for 84 days.
Study NCT00765336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator for 1 mg/kg extended release minocycline HCL, once daily for 84 days.
Study NCT03111680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: environmental intervention
Description: a multi component environmental intervention
Study NCT03852472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Active treatment
Study NCT03852472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01056783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: OC000459 100mg, twice daily, tablet
Study NCT01056783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match OC000459 tablets, twice daily
Study NCT03422068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Tablet formulation
Study NCT03422068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet formulation
Study NCT00410813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: given orally
Study NCT01417247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic modification
Description: Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
Study NCT00216580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, long-acting injectable
Study NCT01742130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate solution
Study NCT01742130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Study NCT01534338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
Study NCT01534338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
Study NCT03062930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Track 1
Description: Training of non-paretic arm followed by sham condition
Study NCT03062930 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Track 1
Description: Training of non-paretic arm followed by sham condition
Study NCT03062930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Track 2
Description: Same procedures as track 1, but completed in opposite order, starting with sham condition followed by the non-paretic arm training
Study NCT03062930 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Track 2
Description: Same procedures as track 1, but completed in opposite order, starting with sham condition followed by the non-paretic arm training
Study NCT03096314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 540,000 IU vitamin D3 delivered as a single, liquid enteral dose administered either orally or via naso/orogastric tube
Study NCT03096314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single, liquid enteral dose identical in appearance and consistency to cholecalciferol administered either orally or via naso/orogastric tube.
Study NCT01397877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: per os, 60mg/j, until progression or unacceptable toxicity
Study NCT02829320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.
Study NCT02829320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: Subjects will receive supplemental iron therapy if ferritin is \<=100 ng/mL and TSAT is \<=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
Study NCT03326570 — intervention group
Intervention type: BEHAVIORAL
Intervention: Medical Data Collection
Description: Medical information collected after bronchoscopy for up to 2 years.
Study NCT02841995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: Pharmaceutical form: Capsules or Tablets Route of administration: Oral
Study NCT01411800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg capsule
Description: Two 250 mg capsules will be administered for 500 mg dose
Study NCT01411800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg tablets
Description: Two 250 mg tablets will be administered for a 500 mg dose
Study NCT01504464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: intra articular injection of mesenchymal stem cell
Study NCT01504464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients with knee joint osteoarthritis who underwent intra articular placebo injection
Study NCT03448419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Film-coated tablet
Study NCT03448419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study NCT01506401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensorMedics 3100B High Frequency Oscillatory Ventilator
Description: High Frequency Oscillation
Study NCT01506401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Protective Ventilation
Description: Tidal Volume 6ml/kg; plateau pressure \< or = 35cmH20; Prescribed PEEP/FiO2 chart
Study NCT02348918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 1.0mg
Study NCT02348918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 2.0mg
Study NCT02348918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 3.0mg
Study NCT02348918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Study NCT02348918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 0.5mg
Study NCT02213172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum R0175
Study NCT02213172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei HA-196
Study NCT02003001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Study NCT02564523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles)
Study NCT02564523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 mL IM injection of (1x10\*8 infectious units)
Study NCT02564523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline
Study NCT02414893 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: Laparoscopic vertical gastrectomy as a bariatric procedure.
Study NCT02213172 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02343939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Tablet(s) administered orally every 12 hours
Study NCT03892681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hepatocyte-specific contrast agent, extracellular contrast agent
Description: The type of contrast agent for the 1st MRI will be performed using hepatocyte-specific contrast agent (Primovist). The participant will undergo the 2nd MRI using extracellular contrast agent (Gadovist).
Study NCT04108377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast capsule
Study NCT04108377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic look of Roflumilast capsule
Study NCT04532541 — intervention group
Intervention type: OTHER
Intervention: Monogenic lupus screening
Description: This is an observational study, and there is no intervention. This study intends to obtain the incidence of monogenic lupus in childhood onset SLE through gene test and bioinformatic analysis.
Study NCT01548469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio Mineral toothpaste
Description: Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
Study NCT01548469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Perio Total Care toothpaste
Description: Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
Study NCT00289627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab (MDX-010, BMS-734016)
Description: IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Study NCT02751333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FCSEMS with Endostitch (ES)
Description: The fixation of FCSEMS using endostitch (ES) with the OverStitchTM system to prevent migration.
Study NCT02751333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FCSEMS with No Suturing (NS)
Description: The insertion of FCSEMS with no suturing.
Study NCT02751333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fully Covered Self-Expanding Metal Stents (FCSEMS)
Description: This is the stent that will be used to treat the esophageal pathology in both groups
Study NCT02751333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoStitch (ES) with the OverStitchTM system
Description: This is the device used to apply the stitches to the stent in participants randomized to stent suturing.
Study NCT02457624 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education and feedback
Description: Experienced endoscopists will receive education on Kimura-Takemoto classification and feedback for their answers for classification tests.
Study NCT01501383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-765 Part A
Description: Tablets of VX-765 given at different doses based on treatment group in Part A
Study NCT01501383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01501383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-765 Part B
Description: Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B